NCT03816683Completed
A Disease Registry of Patients With Mantle Cell Lymphoma
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents
Source: ClinicalTrials.gov · Last updated 14 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 6 months and whose treatment is ongoing at the time of enrollment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 227 (actual)
- First submitted
- 10 Dec 2018
- Start date
- 1 Apr 2019
- Primary completion date
- 18 Mar 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Mantle cell lymphoma
- NCT number
- NCT03816683
What you commit to
- Study type: Observational
- Participants enrolled: 227
- From 1 Apr 2019 to the primary completion date, 18 Mar 2024
- 29 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient is participating in a clinical study that prohibits participation in non-interventional studies, or where treatment is blinded, at the time of consent.
Who the study is looking for
- Patient diagnosed with Mantle Cell Lymphoma (MCL)
- Informed consent for participation
- Age ≥ 18 years old, as of the first observed diagnosis of MCL
- Patients for whom a clinical decision has been made to initiate novel therapy in the last 6 months, limited to the following novel agent categories:
- Bcl-2 inhibitors
- BTK inhibitors
- Immunomodulatory agents
- Phosphoinositide 3-kinase inhibitors The novel agent must have been granted approval in at least one haematological cancer. Treatment must be ongoing at the time of enrollment.
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (29)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.